POS12 THE DIFFUSION OF NEW DRUG IN TAIWAN MEDICAL CARE UNDER NATIONAL HEALTH INSURANCE: THE CASE OF COX2
Tsai YW 1 , Huang WF 2 , Wen YW 3 , Chen PF 3 1 National Health Research Institutes, Zhunan Town, Taiwan, 2 National Yang-Ming University, Taipei, Taiwan, 3 National Health Research Institutes, Miaoli County, Taiwan OBJECTIVES: Adoption of new drug in medical care, a highlyregulated industry, is and essential in terms of access to new treatment option and raise on health care expenditure. This study, using Cox2 as example, is to examine the diffusion of new drug among hospitals of different characteristics. METHOD: The data were drawn from systematic random sample of NHI claim data in 1997 to 2001. We applied the Bass diffusion model to analyze the monthly number of each hospital's outpatient clinic visits with COX2. Bass diffusion model based on the initial time of purchase of product to explains the behavior of the diffusion of the product in the market: length to reach maximum monthly volume, maximum monthly volume, growth rate. RESULTS: The estimates of Bass diffusion model shows that the monthly numbers of outpatient clinic visits with COX2 prescription reached the stable maximum in the 92th month, 41 months after the introduction of COX2 on April of 2001. The length of growth period for reaching maximum volume varied with different accreditation level of hospital: academic medical center 38 months, metropolitan hospitals 43 months, local community hospitals 40 months, and physician clinics 51 months. The average of maximum volume for academic center was 76.17 outpatient visits, metropolitan hospitals 87.25 visits, local community hospitals 62.65 visits, and physician clinics 34.38 visits. Physician clinics has the fast growth rate (q = 0.1278), in contrast to the slowest of local community hospitals (q = 0.1159), CONCLUSION: Hospitals of different level vary in terms of adopting new drugs. Academic medical centers play the role of innovators. Data on fracture and mortality risks were obtained from the General Practice Research Database. These risks were estimated individually by age, sex, fracture history, body mass index, smoking and other risk factors. EQ5D utilities were obtained from a UK national report (NICE) and outcomes were simulated over a 10-year period (5-year treatment), using a costacceptability ratio of £30k per QALY gained. RESULTS: The 5-year risk of osteoporotic fracture required to reach the costeffectiveness threshold was 17.1% (95% confidence interval 15.0-19.3%) with a fracture efficacy of 0.50 at an annual cost of £1000. This was 6.1% (5.2-7.0%) with a cost of £250 and 3.7% (3.1-4.5% with a cost of £100. With a fracture efficacy of only 0.80, these threshold risks were 34.7% (23.2-38.7%), 10.7% (8.3-14.5%) and 5.4% (3.8-7.8%), respectively. At a Tscore of −2.5 and fracture efficacy of 0.80 and cost of £250, patients without a fracture history would require additional risk factors (with a relative rate of 2.5) in order to reach the threshold, while this would be reached by the average woman at age 85. However, with a cost of £1000, this threshold would only be reached at age 55 with additional risk factors with RR of 9.5 and at age 85 with RR of 3.0. CONCLUSION: Costeffectiveness thresholds can be estimated prior to expensive clinical trials using high-quality health care databases. Similar to statistical power calculations, they can then be used to guide patient selection into the clinical trials, by providing information on the required minimum levels of risks.
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